Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Jan 28, 2020 1:56pm
72 Views
Post# 30609767

RE:RE:Corona-virus and clinical recruitment

RE:RE:Corona-virus and clinical recruitmentWell I guess I need to flesh this out more since you didnt get the point.

1- the virus has reached both southern ontario and quebec.  The following link has a live map of confimed cases: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
2- the average infected person can pass it to between 1.5 to 3.5 people per day
3-the confirmed case in ontario came from Wuhan. All the people on that flight are at risk. 
4-several people who were made aware that they were on the same flight as the confirmed case from Wuhan in Ontario, have reported it. So in the few days between releazing the report and reporting the infection to POC in whatever clinic/emerg, could have even more people infected. 
5- We have recruitment sites all across the country. Most are concentrated in ontario.
6-connect the dots from here, son.

Pandora wrote:
themagicbox wrote: I wonder if this coronovirus scare could affect the patient recruitment for this study?

We're looking for older adults with OA and no other comorbidity. Would they risk getting infected travelling to sites?

Its hit ontario and quebec as of today.


And if those 'patients' travelled from China to Ontario/Quebec what was their means of travel? Plane? And, if so, was that a direct flight with how many "exposed" fellow passengers. And if it was not a direct flight where else did it touch down? Did exposed fellow passengers disembark? Where are they now. Did the target patient possibly change planes and expose how many other fellow passengers?

So many unanswered questions on how a disease such as this can spread far and wide.



Bullboard Posts